Antifungal therapeutic drug monitoring

被引:23
作者
Lewis R.E. [1 ]
机构
[1] University of Houston College of Pharmacy, University of Texas M.D. Anderson Cancer Center, Texas Medical Center Campus, Houston, TX 77030
关键词
Antifungal agents; Antifungals; Fungal infections; Itraconazole; Pharmacokinetics; Pharmacology; Posaconazole; TDM; Therapeutic drug monitoring; Triazoles; Voriconazole;
D O I
10.1007/s12281-010-0023-9
中图分类号
学科分类号
摘要
A growing body of evidence suggests that patient-to-patient variability in the pharmacokinetics of some antifungals, particularly the mold-active triazoles (itraconazole, voriconazole, and posaconazole) may contribute to therapeutic failure or unexpected toxicity. As a result, many clinicians have recognized a need for therapeutic drug monitoring (TDM) to individualize drug dosing in select patients with suspected or documented invasive fungal infections. However, approaches for performing and interpreting plasma concentrations are not well standardized, and logistical issues such as the turnaround time of test results can limit the clinical usefulness of testing in acutely ill patients. This article summarizes the pharmacologic rationale for TDM of antifungal agents, with a particular focus on recently published data for the newer triazoles, voriconazole and posaconazole. Practical recommendations for TDM-guided dosing are also provided, based on a critical evaluation of literature published over the past 5 years. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码:158 / 167
页数:9
相关论文
共 76 条
  • [11] Summers K.K., Hardin T.C., Gore S.J., Graybill J.R., Therapeutic drug monitoring of systemic antifungal therapy, Journal of Antimicrobial Chemotherapy, 40, 6, pp. 753-764, (1997)
  • [12] Bruggemann R.J., Touw D.J., Aarnoutse R.E., Et al., International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations, Antimicrob Agents Chemother, 53, pp. 303-305, (2009)
  • [13] Trifilio S.M., Bennett C.L., Yarnold P.R., McKoy J.M., Parada J., Mehta J., Chamilos G., Palella F., Kennedy L., Mullane K., Tallman M.S., Evens A., Scheetz M.H., Blum W., Kontoyiannis D.P., Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy, Bone Marrow Transplantation, 39, 7, pp. 425-429, (2007)
  • [14] Trifilio S., Singhal S., Williams S., Et al., Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole, Bone Marrow Transplant, 40, pp. 451-456, (2007)
  • [15] Hope W.W., Billaud E.M., Lestner J., Denning D.W., Therapeutic drug monitoring for triazoles, Curr Opin Infect Dis, 21, pp. 580-586, (2008)
  • [16] Trifilio S.M., Yarnold P.R., Scheetz M.H., Et al., Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation, Antimicrob Agents Chemother, 53, pp. 1793-1796, (2009)
  • [17] Bennett J.E., Dismukes W.E., Duma R.J., A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis, New England Journal of Medicine, 301, 3, pp. 126-131, (1979)
  • [18] Van D.H.C.M., Saag M.S., Cloud G.A., Hamill R.J., Graybill J.R., Sobel J.D., Johnson P.C., Tuazon C.U., Kerkering T., Moskovitz B.L., Powderly W.G., Dismukes W.E., Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome, New England Journal of Medicine, 337, 1, pp. 15-21, (1997)
  • [19] Andes D., Van Ogtrop M., In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model, Antimicrob Agents Chemother, 44, pp. 938-942, (2000)
  • [20] Groll A.H., Piscitelli S.C., Walsh T.J., Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development, Adv Pharmacol, 44, pp. 343-500, (1998)